Skip to main content

Table 3 APOE, APOAI, and APOB concentrations [mg/dl] in serum and in lipoprotein fractions in the study groups

From: Apolipoprotein E gene polymorphism and renal function are associated with apolipoprotein E concentration in patients with chronic kidney disease

Parameter Total APOE subgroup P value
E2 E3 E4
APOE 4.08 ± 1.27 4.94 ± 1.47 4.00 ± 1.15 3.34 ± 0.80 < 0.001*
APOE-HDL 1.45 ± 0.60 2.08 ± 1.15 1.38 ± 0.50 0.90 ± 0.34 < 0.001**
APOE-non-HDL 2.66 ± 0.93 2.86 ± 1.15 2.64 ± 0.92 2.44 ± 0.66 0.43
APOE-IDL + LDL 2.06 ± 0.85 2.23 ± 1.25 2.09 ± 0.72 1.70 ± 0.62 0.23
APOE-VLDL 0.57 ± 0.42 0.63 ± 0.52 0.51 ± 0.37 0.70 ± 0.44 0.23
APOAI 168 ± 30 178 ± 33 166 ± 30 164 ± 25 0.49
APOE-HDL/APOAI 0.0086 ± 0.0031 0.0117 ± 0.0019 0.0082 ± 0.0027 0.0056 ± 0.0023 < 0.0001***
APOB 94 ± 25 91 ± 11 95 ± 27 97 ± 30 0.95
APOB-IDL + LDL 85 ± 24 81 ± 12 85 ± 25 87 ± 37 0.97
APOB-VLDL 8.8 ± 4.2 9.4 ± 4.2 8.1 ± 4.0 10.7 ± 4.4 0.08
APOE/APOB in non-HDL 0.029 ± 0.0085 0.032 ± 0.012 0.029 ± 0.0074 0.026 ± 0.0068 0.40
APOE/APOB in IDL + LDL 0.025 ± 0.010 0.028 ± 0.015 0.025 ± 0.0082 0.021 ± 0.0073 0.15
APOE/APOB in VLDL 0.071 ± 0.044 0.070 ± 0.046 0.071 ± 0.044 0.073 ± 0.045 0.95
  1. Values are presented as mean ± SD. Differences among the subgroups were analysed using ANOVA and test post hoc Tukey’s test
  2. APOE - apolipoprotein E, APOAI - apolipoprotein AI, APOB - apolipoprotein B, non-HDL - non-high density lipoprotein (VLDL + IDL + LDL), HDL - high density lipoprotein, VLDL - very low-density lipoprotein, IDL - intermediate density lipoprotein, LDL - low density lipoprotein
  3. Subgroups: E2: ɛ2ɛ3 subjects; E3: ɛ3ɛ3 subjects; E4: ɛ3ɛ4 subjects
  4. * E2 vs E4 p = 0.002, E2 vs E3 p = 0.052, E3 vs E4 p = 0.291, ** E2 vs E4 p < 0.001, E2 vs E3 p < 0.001, E3 vs E4 p = 0.039, *** E2 vs E4 p < 0.001, E2 vs E3 p < 0.001, E3 vs E4 p = 0.016